ArticleOpen forum infectious diseases2025

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study.

Emma Birnie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.